Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208.-MedSci.cn

Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208.

Hochster, HS; Catalano, PJ; O'Dwyer, PJ; Mitchell, EP; Cohen, DJ; Faller, BA

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (15):

科室
- - 订阅+
  - 更多科室
工具
服务